.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Find suppliers and generic API sources
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
Novartis
Baxter
Deloitte
Farmers Insurance
Boehringer Ingelheim
Fish and Richardson
Chinese Patent Office
QuintilesIMS
AstraZeneca

Generated: July 21, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,367,701

« Back to Dashboard

Which drugs does patent 8,367,701 protect, and when does it expire?


Patent 8,367,701 protects XIIDRA and is included in one NDA.

This patent has thirty patent family members in seven countries.

Summary for Patent: 8,367,701

Title:Crystalline pharmaceutical and methods of preparation and use thereof
Abstract: Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention. ##STR00001##
Inventor(s): Burnier; John (Pacifica, CA), Gadek; Thomas (Oakland, CA), Naud; Frederic (Binningen, CH)
Assignee: SARcode Bioscience Inc. (Brisbane, CA)
Application Number:13/289,172
Patent Claim Types:
see list of patent claims
Composition; Compound; Use; Formulation; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Shire Dev Llc
XIIDRA
lifitegrast
SOLUTION/DROPS;OPHTHALMIC208073-001Jul 11, 2016RXYesYes8,367,701► SubscribeY TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,367,701

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,080,562Crystalline pharmaceutical and methods of preparation and use thereof► Subscribe
9,447,077Crystalline pharmaceutical and methods of preparation and use thereof► Subscribe
8,871,935Crystalline pharmaceutical and methods of preparation and use thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,367,701

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China101873797► Subscribe
China102056485► Subscribe
China102065694► Subscribe
China102065893► Subscribe
China105943534► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
QuintilesIMS
Federal Trade Commission
UBS
Accenture
Fish and Richardson
Fuji
Merck
Cerilliant
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot